Vanda Pharmaceuticals Inc (VNDA.OQ)
21 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|64||2014||Independent Chairman of the Board|
|57||2010||President, Chief Executive Officer, Director|
|51||2017||Chief Financial Officer, Executive Vice President, Treasurer|
|51||2016||Senior Vice President, Chief Compliance Officer|
|54||2015||Senior Vice President, General Counsel, Secretary|
- BRIEF-Vanda Pharmaceuticals Qtrly Net Loss Per Share $0.04
- BRIEF-Vanda receives negative opinion for marketing authorization from the European Medicines Agency
- BRIEF-Vanda Pharmaceuticals posts qtrly net loss of $0.10/share
- BRIEF-Vanda Pharmaceuticals reached a pricing agreement with the German National Association of Statutory Health Insurance Funds
- BRIEF-Vanda Pharmaceutical announced results from study of Tradipitant as a treatment of chronic pruritus